Kyzatrex

6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed elsewhere in the labeling: Increase in Blood Pressure [see Warnings and Precautions (5.1) ] Polycythemia [see Warnings and Precautions (5.2) ] Cardiovascular Risk [see Warnings and Precautions (5.3) ] Worsening of Benign Prostatic Hyperplasia (BPH) and Potential Risk of Prostate Cancer [ see Warnings and Precautions (5.4) ] Venous Thromboembolism [see Warnings and Precautions (5.5) ] Hepatic Adverse Effects [see Warnings and Precautions (5.9) ] Edema [see Warnings and Precautions (5.10) ] Sleep Apnea [see Warnings and Precautions (5.11) ] Gynecomastia [see Warnings and Precautions (5.12) ] Lipid Changes [see Warnings and Precautions (5.13) ] Hypercalcemia [see Warnings and Precautions (5.14) ] Decreased Thyroxine-binding Globulin [see Warnings and Precautions (5.15) ] Most common adverse reactions (incidence ≥ 2%): hypertension ( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Marius Pharmaceuticals at 1-833-949-5040 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of KYZATREX™ was evaluated in Study MRS-TU-2019EXT in 155 hypogonadal males [see Clinical Studies (14) ]. All patients initially received KYZATREX™ 200 mg orally twice daily. If needed, the dosage was titrated to 100 mg once daily in the morning or 100 mg, 300 mg, or 400 mg twice daily to achieve testosterone concentrations in the normal range . After the dosage titration period, patients continued their optimized dose for the remainder of the duration of the 6-month study. The mean duration of exposure was 168 days (range: 1 to 180 days). The median age was 52 years (range: 22 to 66 years); 77% were White, 19% were Black, 3% were Asian, and 2% were American Indian, Alaskan Native or Other. Table 2 summarizes adverse reactions reported in ≥2% of patients in this 6-month study. Table 2: Adverse Reactions in ≥ 2% of Patients Receiving KYZATREX™ in STUDY MRS-TU-2019EXT Adverse Reaction N = 155 n (%) Hypertensión Based upon blood pressure cuff measurements 4 (2.6) One (0.8%) patient who received KYZATREX™ experienced an adverse reaction (acne) that lead to premature discontinuation from the study. In a 12-month, open-label study in hypogonadal adult males (N=212) who received KYZATREX™ 200 mg once daily to 400 mg twice daily (n=202) the following additional adverse reactions were reported: headache, arthralgia, diarrhea, hemoglobin increased, anxiety, constipation, peripheral edema, and PSA increased. Blood Pressure Increases Ambulatory (24-hour) and in-clinic (cuff) blood pressure Changes from Baseline for study MRS-TU-2019EXT are presented in Table 3 with 95% confidence intervals. No significant difference was observed between the 4-month and 6-month Changes from Baseline. Table 3: Blood Pressure Increases Blood Pressure Change from Baseline (95% CI) mm Hg Systolic Diastolic 24-Hour Ambulatory 4 Month 1.7 (0.3 to 3.1) 0.6 (-0.3 to 1.6) 6 Month 1.8 (0.3 to 3.2) 0.6 (-0.4 to 1.6) In-clinic (blood pressure cuff) 4 Month 2.7 (0.9 to 4.5) 1.5 (0.3 to 2.6) 6 Month 2.4 (0.6 to 4.2) 1.7 (0.5 to 2.9) A total of 5 of 155 patients (3.2%) in Study MRS-TU-2019EXT began taking new antihypertensive medications after study start. No patient had a dose increase in their antihypertensive medication by the end of treatment. A history of antihypertensive treatment and diabetes mellitus at baseline were significant factors related to ambulatory SBP increases. Table 4 presents the Least Squares Mean estimates of Change from Baseline, with 95% CI's, for sub-populations of subjects at study start either with or without hypertensive treatment or with or without diabetes mellitus. Table 4: Ambulatory Blood Pressure Increases by Subject Sub-group Subgroups Ambulatory Systolic Blood Pressure Change from Baseline (95% CI), mm Hg With hypertensive treatment at baseline (n=49) 4 Month 3.4 (1.0 to 5.9) 6 Month 3.1 (0.6 to 5.6) Without hypertensive treatment at baseline (n=90) 4 Month 0.7 (-1.0 to 2.4) 6 Month 1.0 (-0.7 to 2.8) With diabetes at baseline (n=29) 4 Month 3.0 (-0.2 to 6.2) 6 Month 3.4 (0.2 to 6.7) Without diabetes at baseline (n=110) 4 Month 1.3 (-0.2 to 2.9) 6 Month 1.3 (-0.3 to 2.9) Heart Rate Increases KYZATREX™ increased mean (95%CI) 24-hour ambulatory heart rate by an average of 0.7 (-0.5 to 1.9) beats per minute (bpm) at 4 months and 1.9 (0.6 to 3.1) bpm at 6 months in Study MRS-TU-2019EXT. Changes in heart rate were similar between patients with or without hypertension or diabetes. Changes in heart rate with treatment were most prominent in the evening, 12 to 17 hours after the morning dose. Increases in Hemoglobin Increases in hemoglobin were reported in 7 out of 155 patients (4.5%) in Study MRS-TU2019EXT. None of these increases led to premature discontinuation of KYZATREX™. Hematocrit was not assessed in this study. Headaches Headaches were reported in 3 of 155 patients (1.9%) receiving KYZATREX™ in Study MRSTU-2019EXT. Increases in Serum PSA Four out of 155 patients (2.6%) receiving KYZATREX™ in Study MRS-TU-2019EXT had an increase in PSA from baseline greater than 1.4 ng/mL and two out of 155 patients (1.3%) had a PSA of at least 4.0 ng/mL during Study MRS-TU-2019EXT. The mean (SE) increase in PSA from baseline was 0.15 (±0.04) ng/mL at 6 months (n=135). 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of testosterone. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Cardiovascular Disorders: myocardial infarction, stroke Vascular Disorders: Venous thromboembolism

4 CONTRAINDICATIONS KYZATREX™ is contraindicated in: Patients with carcinoma of the breast or known or suspected carcinoma of the prostate [see Warnings and Precautions (5.4) ] . Women who are pregnant. Testosterone can cause virilization of the female fetus when administered to a pregnant woman [ see Use in Specific Populations (8.1) ]. Patients with known hypersensitivity to KYZATREX™ or any of its ingredients [see Description (11) ] . Men with hypogonadal conditions, such as "age-related hypogonadism," that are not associated with structural or genetic etiologies. The efficacy of KYZATREX™ has not been established for these conditions, and KYZATREX™ can increase BP that can increase the risk of MACE [see Boxed Warning and Warning and Precautions (5.1) ]. Carcinoma of the breast or known or suspected carcinoma of the prostate ( 5.4 ) Women who are pregnant. Testosterone may cause fetal harm ( 4 , 5.7 , 8.1 ) Hypersensitivity to KYZATREX™ or any of its ingredients ( 4 ) Hypogonadal conditions not associated with structural or genetic etiologies ( 4 )

11 DESCRIPTION KYZATREX™ is provided as a gelatin capsule containing testosterone undecanoate, a fatty-acid ester of testosterone. Testosterone undecanoate is a white to off-white yellow crystalline powder. Testosterone, an androgen, is formed by cleavage of the ester side chain of testosterone undecanoate. Testosterone undecanoate is chemically described as 17β-hydroxyandrost-4-en-3-one undecanoate. It has the empirical formula of C 30 H 48 O 3 and a molecular weight of 456.7 g/mol. The structural formula for testosterone undecanoate is presented in Figure 1. Figure 1: Testosterone Undecanoate KYZATREX™ (testosterone undecanoate) capsules for oral use are available in three dosage strengths- 100 mg, 150 mg, and 200 mg. The 100 mg strength is an opaque, white capsule imprinted with "MP100" in red ink. The 150 mg strength is an opaque white capsule imprinted with "MP150" in red ink. The 200 mg strength is an opaque white capsule imprinted with "MP200" in red ink. All capsule strengths also contain DL-alpha-tocopheryl acetate (Vitamin E), phytosterol esters, polyoxyl 40 hydrogenated castor oil, and propylene glycol monolaurate as inactive ingredients. Gelatin capsule shells are composed of the following inactive ingredients: gelatin, glycerin, purified water, sorbitol, and titanium dioxide. Figure 1

2 DOSAGE AND ADMINISTRATION KYZATREX™ is not substitutable with other oral testosterone undecanoate products ( 2.1 ). Prior to initiating KYZATREX™, confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these concentrations are below the normal range ( 2.2 ). Take KYZATREX™ with food ( 2.3 ). Starting dosage: 200 mg orally once in the morning and once in the evening ( 2.3 ). Adjust the dosage to a minimum of 100 mg once in the morning and a maximum of 400 mg twice daily based on serum testosterone drawn 3 to 5 hours after the morning dose at least 7 days after starting treatment or following dose adjustment and periodically thereafter ( 2.3 ). 2.1 Important Dosage Information KYZATREX™ is not substitutable with other oral testosterone undecanoate products. 2.2 Confirmation of Hypogonadism Before Initiation of KYZATREX™ Prior to initiating KYZATREX™, confirm the diagnosis of hypogonadism by ensuring that serum testosterone concentrations have been measured in the morning on at least two separate days and that these testosterone concentrations are below the normal range. 2.3 Recommended Dosage and Administration Individualize the dosage of KYZATREX™ based on the patient's serum testosterone concentration response to the drug. The recommended starting dose is 200 mg orally twice daily, once in the morning and once in the evening. Take KYZATREX™ with food. Dosage Adjustment Check serum testosterone concentrations 7 days after starting treatment or after dosage adjustment, 3 to 5 hours after the morning dose. Adjust the KYZATREX™ dose as necessary as shown in Table 1. Thereafter, periodically monitor serum testosterone concentrations. The minimum recommended dose is 100 mg once daily in the morning. The maximum recommended dose is 400 mg twice daily. For total daily doses greater than 100 mg, administer the same dose in the morning and evening. Table 1: KYZATREX™ Dosage Adjustment Scheme Serum Testosterone Concentration Current KYZATREX™ Dosage New KYZATREX™ Dosage Less than 460 ng/dL 100 mg with breakfast only 100 mg twice daily with meals 100 mg twice daily with meals 200 mg twice daily with meals 200 mg twice daily with meals 300 mg twice daily with meals 300 mg twice daily with meals 400 mg twice daily with meals 460 to 971 ng/dL No Dosage Change More than 971 ng/dL 400 mg twice daily with meals 300 mg twice daily with meals 300 mg twice daily with meals 200 mg twice daily with meals 200 mg twice daily with meals 100 mg twice daily with meals 100 mg twice daily with meals 100 mg with breakfast only 100 mg with breakfast only Discontinue treatment

1 INDICATIONS AND USAGE KYZATREX™ is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (folliclestimulating hormone (FSH), luteinizing hormone (LH)) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low serum testosterone concentrations but have gonadotropins in the normal or low range. KYZATREX™ is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone ( 1 ). Limitations of Use: Safety and efficacy of KYZATREX™ in males less than 18 years old have not been established ( 1 , 8.4 ). Limitations of Use Safety and efficacy of KYZATREX™ in males less than 18 years old have not been established [see Use in Specific Populations (8.4) ] .

9.2 Abuse Drug abuse is intentional non-therapeutic use of a drug, even once, for its rewarding psychological and physiological effects. Abuse and misuse of testosterone are seen in male and female adults and adolescents. Testosterone, often in combination with other anabolic androgenic steroids, and not obtained by prescription through a pharmacy, may be abused by athletes and bodybuilders. There have been reports of misuse by men taking higher doses of legally obtained testosterone than prescribed and continuing testosterone despite adverse events or against medical advice. Abuse-Related Adverse Reactions Serious adverse reactions have been reported in individuals who abuse anabolic androgenic steroids and include cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and serious psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility, and aggression. The following adverse reactions have also been reported in men: transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemias, testicular atrophy, subfertility, and infertility. The following additional adverse reactions have been reported in women: hirsutism, virilization, deepening of voice, clitoral enlargement, breast atrophy, male-pattern baldness, and menstrual irregularities. The following adverse reactions have been reported in male and female adolescents: premature closure of bony epiphyses with termination of growth, and precocious puberty. Because these reactions are reported voluntarily from a population of uncertain size and may include abuse of other agents, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

9.1 Controlled Substance KYZATREX™ contains testosterone undecanoate, a Schedule III controlled substance

9.3 Dependence Behaviors Associated with Addiction Continued abuse of testosterone and other anabolic steroids leading to addiction is characterized by the following behaviors: Taking greater dosages than prescribed Continued drug use despite medical and social problems due to drug use Spending significant time to obtain the drug when supplies of the drug are interrupted Giving a higher priority to drug use than other obligations Having difficulty in discontinuing the drug despite desires and attempts to do so Experiencing withdrawal symptoms upon abrupt discontinuation of use Physical dependence is characterized by withdrawal symptoms after abrupt drug discontinuation or a significant dose reduction of a drug. Individuals taking supratherapeutic doses of testosterone may experience withdrawal symptoms lasting for weeks or months, which may include depressed mood, major depression, fatigue, craving, restlessness, irritability, anorexia, insomnia, decreased libido, and hypogonadotropic hypogonadism. Drug dependence in individuals using approved doses of testosterone for approved indications has not been documented.

9 DRUG ABUSE AND DEPENDENCE 9.1 Controlled Substance KYZATREX™ contains testosterone undecanoate, a Schedule III controlled substance 9.2 Abuse Drug abuse is intentional non-therapeutic use of a drug, even once, for its rewarding psychological and physiological effects. Abuse and misuse of testosterone are seen in male and female adults and adolescents. Testosterone, often in combination with other anabolic androgenic steroids, and not obtained by prescription through a pharmacy, may be abused by athletes and bodybuilders. There have been reports of misuse by men taking higher doses of legally obtained testosterone than prescribed and continuing testosterone despite adverse events or against medical advice. Abuse-Related Adverse Reactions Serious adverse reactions have been reported in individuals who abuse anabolic androgenic steroids and include cardiac arrest, myocardial infarction, hypertrophic cardiomyopathy, congestive heart failure, cerebrovascular accident, hepatotoxicity, and serious psychiatric manifestations, including major depression, mania, paranoia, psychosis, delusions, hallucinations, hostility, and aggression. The following adverse reactions have also been reported in men: transient ischemic attacks, convulsions, hypomania, irritability, dyslipidemias, testicular atrophy, subfertility, and infertility. The following additional adverse reactions have been reported in women: hirsutism, virilization, deepening of voice, clitoral enlargement, breast atrophy, male-pattern baldness, and menstrual irregularities. The following adverse reactions have been reported in male and female adolescents: premature closure of bony epiphyses with termination of growth, and precocious puberty. Because these reactions are reported voluntarily from a population of uncertain size and may include abuse of other agents, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. 9.3 Dependence Behaviors Associated with Addiction Continued abuse of testosterone and other anabolic steroids leading to addiction is characterized by the following behaviors: Taking greater dosages than prescribed Continued drug use despite medical and social problems due to drug use Spending significant time to obtain the drug when supplies of the drug are interrupted Giving a higher priority to drug use than other obligations Having difficulty in discontinuing the drug despite desires and attempts to do so Experiencing withdrawal symptoms upon abrupt discontinuation of use Physical dependence is characterized by withdrawal symptoms after abrupt drug discontinuation or a significant dose reduction of a drug. Individuals taking supratherapeutic doses of testosterone may experience withdrawal symptoms lasting for weeks or months, which may include depressed mood, major depression, fatigue, craving, restlessness, irritability, anorexia, insomnia, decreased libido, and hypogonadotropic hypogonadism. Drug dependence in individuals using approved doses of testosterone for approved indications has not been documented.

10 OVERDOSAGE There is one report of acute overdosage with use of an approved injectable testosterone product: this subject had serum testosterone levels of up to 11,400 ng/dL with a cerebrovascular accident. Treatment of overdosage consists of discontinuation of KYZATREX™ and appropriate symptomatic and supportive care.

7 DRUG INTERACTIONS Insulin: In patients with diabetes, concomitant use with KYZATREX™ may decrease blood glucose and insulin requirements ( 7.1 ). Oral Anticoagulants: Concomitant use with KYZATREX™ may cause changes in anticoagulant activity. Monitor International Normalized Ratio (INR) and prothrombin time (PT) frequently ( 7.2 ). Corticosteroids: Concomitant use with KYZATREX™ may result in increased fluid retention. Use with caution, particularly in patients with cardiac, renal, or hepatic disease ( 7.3 ). Drugs that May Also Increase Blood Pressure: Concomitant use with KYZATREX™ may lead to additional increases in blood pressure ( 7.4 ). 7.1 Insulin Changes in insulin sensitivity or glycemic control may occur in patients treated with androgens. In diabetic patients, the metabolic effects of androgens may decrease blood glucose and therefore necessitate a decrease in the dose of anti-diabetic medication. 7.2 Oral Vitamin K Antagonist Anticoagulants Changes in anticoagulant activity may be seen with androgens; therefore, more frequent monitoring of international normalized ratio (INR) and prothrombin time are recommended in patients taking warfarin, especially at the initiation and termination of androgen therapy. 7.3 Corticosteroids The concurrent use of testosterone with corticosteroids may result in increased fluid retention and requires careful monitoring particularly in patients with cardiac, renal, or hepatic disease. 7.4 Medications that May Also Increase Blood Pressure Some prescription medications and nonprescription analgesic and cold medications contain drugs known to increase blood pressure. Concomitant administration of these medications with KYZATREX™ may lead to additional increases in blood pressure [see Warnings and Precautions (5.1) ].

12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Endogenous androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis, and scrotum; the development of male hair distribution, such as facial, pubic, chest, and axillary hair; laryngeal enlargement; vocal cord thickening; alterations in body musculature; and fat distribution. Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone, has two main etiologies. Primary hypogonadism is caused by defects of the gonads, such as Klinefelter syndrome or Leydig cell aplasia, whereas secondary hypogonadism (also known as hypogonadotropic hypogonadism) is the failure of the hypothalamus (or pituitary gland) to produce sufficient gonadotropins (FSH, LH). 12.2 Pharmacodynamics There is insufficient data to characterize an exposure-response relationship or time course of pharmacodynamics. 12.3 Pharmacokinetics Absorption KYZATREX™ was taken orally at a starting dose of 200 mg twice per day with meals in a multicenter, open-label trial in hypogonadal males. The dose was adjusted, as needed, on Days 28 and 56 from a minimum dose of 100 mg (morning-only) to a maximum dose of 400 mg twice per day based on the plasma testosterone concentration obtained by a single blood draw collected 3 to 5 hours after the morning dose. The average daily NaF/EDTA plasma testosterone concentration was 393.3 (±113.6) ng/dL after 90 days of treatment (normal eugonadal range in NaF/EDTA plasma: 222-800 ng/dL. Note that the titration scheme for use in clinical practice is based on serum total testosterone [see Dosage and Administration (2.2) ] . KYZATREX™ is expected to produce testosterone concentrations that approximate normal concentrations seen in healthy men. Table 5 summarizes the pharmacokinetic (PK) parameters for plasma total testosterone in patients completing at least 90 days of KYZATREX™ treatment administered daily. Table 5: NaF-EDTA Plasma Testosterone C avg and C max at Day 90 Visit PK Parameter Plasma (N=130) PK = pharmacokinetic; C avg = 24-hour average concentration; C max = maximum concentration C avg (ng/dL) n 127 Mean 393.3 SD 113.6 C max (ng/dL) n 130 Mean 852.4 SD 311.3 Figure 2 summarizes the mean plasma total testosterone profile at the final PK visit. Figure 2: Mean (±SEM) Concentration-Time Profile for NaF-EDTA Plasma Total Testosterone in KYZATREX™-Treated Patients at Day 90 Visit SEM = standard error of the mean Testosterone normal ranges: plasma = 222-800 ng/dL When KYZATREX™ was given with breakfast containing 16%, 33%, and 45% fat, the exposure (AUC 0-24 hr ) of testosterone was increased by 37%, 87%, and 94%, respectively, compared to when given under fasted conditions. The primary efficacy and safety study was conducted under fed conditions regardless of the type of meals and the primary efficacy endpoint of achieving testosterone C avg in normal testosterone range was met. There was no effect on testosterone PK when KYZATREX™ was administered with 20% alcohol along with a high-fat meal versus a high-fat meal alone. Figure 2 Distribution Circulating testosterone is primarily bound in serum to sex hormone-binding globulin (SHBG) and albumin. Approximately 40% of testosterone in plasma is bound to SHBG, 2% remains unbound (free), and the rest is loosely bound to albumin and other proteins. Metabolism The androgenic activity of testosterone undecanoate occurs after the ester bond linking the testosterone to the undecanoic acid is cleaved by endogenous non-specific esterases. Undecanoic acid is metabolized like all fatty acids via the beta-oxidation pathway. Testosterone is metabolized to various 17-keto steroids through two different pathways. The major active metabolites of testosterone are dihydrotestosterone (DHT) and estradiol. Excretion About 90% of a dose of testosterone given intramuscularly is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites. About 6% of a dose is excreted in the feces, mostly in the unconjugated form. Inactivation of testosterone occurs primarily in the liver.

12.1 Mechanism of Action Endogenous androgens, including testosterone and dihydrotestosterone (DHT), are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of prostate, seminal vesicles, penis, and scrotum; the development of male hair distribution, such as facial, pubic, chest, and axillary hair; laryngeal enlargement; vocal cord thickening; alterations in body musculature; and fat distribution. Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone, has two main etiologies. Primary hypogonadism is caused by defects of the gonads, such as Klinefelter syndrome or Leydig cell aplasia, whereas secondary hypogonadism (also known as hypogonadotropic hypogonadism) is the failure of the hypothalamus (or pituitary gland) to produce sufficient gonadotropins (FSH, LH).

12.2 Pharmacodynamics There is insufficient data to characterize an exposure-response relationship or time course of pharmacodynamics.

12.3 Pharmacokinetics Absorption KYZATREX™ was taken orally at a starting dose of 200 mg twice per day with meals in a multicenter, open-label trial in hypogonadal males. The dose was adjusted, as needed, on Days 28 and 56 from a minimum dose of 100 mg (morning-only) to a maximum dose of 400 mg twice per day based on the plasma testosterone concentration obtained by a single blood draw collected 3 to 5 hours after the morning dose. The average daily NaF/EDTA plasma testosterone concentration was 393.3 (±113.6) ng/dL after 90 days of treatment (normal eugonadal range in NaF/EDTA plasma: 222-800 ng/dL. Note that the titration scheme for use in clinical practice is based on serum total testosterone [see Dosage and Administration (2.2) ] . KYZATREX™ is expected to produce testosterone concentrations that approximate normal concentrations seen in healthy men. Table 5 summarizes the pharmacokinetic (PK) parameters for plasma total testosterone in patients completing at least 90 days of KYZATREX™ treatment administered daily. Table 5: NaF-EDTA Plasma Testosterone C avg and C max at Day 90 Visit PK Parameter Plasma (N=130) PK = pharmacokinetic; C avg = 24-hour average concentration; C max = maximum concentration C avg (ng/dL) n 127 Mean 393.3 SD 113.6 C max (ng/dL) n 130 Mean 852.4 SD 311.3 Figure 2 summarizes the mean plasma total testosterone profile at the final PK visit. Figure 2: Mean (±SEM) Concentration-Time Profile for NaF-EDTA Plasma Total Testosterone in KYZATREX™-Treated Patients at Day 90 Visit SEM = standard error of the mean Testosterone normal ranges: plasma = 222-800 ng/dL When KYZATREX™ was given with breakfast containing 16%, 33%, and 45% fat, the exposure (AUC 0-24 hr ) of testosterone was increased by 37%, 87%, and 94%, respectively, compared to when given under fasted conditions. The primary efficacy and safety study was conducted under fed conditions regardless of the type of meals and the primary efficacy endpoint of achieving testosterone C avg in normal testosterone range was met. There was no effect on testosterone PK when KYZATREX™ was administered with 20% alcohol along with a high-fat meal versus a high-fat meal alone. Figure 2 Distribution Circulating testosterone is primarily bound in serum to sex hormone-binding globulin (SHBG) and albumin. Approximately 40% of testosterone in plasma is bound to SHBG, 2% remains unbound (free), and the rest is loosely bound to albumin and other proteins. Metabolism The androgenic activity of testosterone undecanoate occurs after the ester bond linking the testosterone to the undecanoic acid is cleaved by endogenous non-specific esterases. Undecanoic acid is metabolized like all fatty acids via the beta-oxidation pathway. Testosterone is metabolized to various 17-keto steroids through two different pathways. The major active metabolites of testosterone are dihydrotestosterone (DHT) and estradiol. Excretion About 90% of a dose of testosterone given intramuscularly is excreted in the urine as glucuronic and sulfuric acid conjugates of testosterone and its metabolites. About 6% of a dose is excreted in the feces, mostly in the unconjugated form. Inactivation of testosterone occurs primarily in the liver.

20231026

15

3 DOSAGE FORMS AND STRENGTHS Capsules: 100 mg, oval, opaque, white, imprinted with "MP100" in red ink 150 mg, oblong, opaque, white, imprinted with "MP150" in red ink 200 mg, oblong, opaque, white, imprinted with "MP200" in red ink Capsules: 100 mg, 150 mg, 200 mg ( 3 ).

Kyzatrex TESTOSTERONE UNDECANOATE PROPYLENE GLYCOL MONOLAURATE POLYOXYL 40 HYDROGENATED CASTOR OIL .ALPHA.-TOCOPHEROL GELATIN, UNSPECIFIED SORBITOL GLYCERIN WATER TITANIUM DIOXIDE TESTOSTERONE UNDECANOATE TESTOSTERONE opaque Oval MP100 Kyzatrex TESTOSTERONE UNDECANOATE PROPYLENE GLYCOL MONOLAURATE POLYOXYL 40 HYDROGENATED CASTOR OIL .ALPHA.-TOCOPHEROL GELATIN, UNSPECIFIED SORBITOL GLYCERIN WATER TITANIUM DIOXIDE TESTOSTERONE UNDECANOATE TESTOSTERONE opaque Oblong MP150 Kyzatrex TESTOSTERONE UNDECANOATE POLYOXYL 40 HYDROGENATED CASTOR OIL .ALPHA.-TOCOPHEROL GELATIN, UNSPECIFIED SORBITOL GLYCERIN WATER TITANIUM DIOXIDE TESTOSTERONE UNDECANOATE TESTOSTERONE PROPYLENE GLYCOL MONOLAURATE opaque Oblong MP200

13.2 Animal Toxicology and/or Pharmacology A 3-month repeat-dose oral toxicity study in male eugonadal dogs was conducted to evaluate whether phytosterol esters present in the KYZATREX™ formulation influenced target organ toxicity due to their structural similarities to sex steroids like testosterone. KYZATREX™ doses 2 times the MRHDD (based on mean AUC exposure to testosterone) produced similar effects on androgen-responsive tissues as testosterone undecanoate without phytosterol esters. These included mild to marked effects on the testes (decreased size, germ cell depletion, Leydig cell atrophy), epididymides (aspermia), adrenal glands (vacuolation in the zona fasciculata) and prostate (increased size and glandular hypertrophy/hyperplasia). Following a 4-week treatment-free period, findings in the testes, epididymides, and adrenal glands were not fully reversible at doses of 2 times the MRHDD of KYZATREX™ as compared to treatment with the excipients alone, including phytosterol esters. Reversibility was not assessed in testosterone undecanoate groups without phytosterol esters.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Testosterone has been tested by subcutaneous injection and implantation in mice and rats. In mice, the implant induced cervical-uterine tumors, which metastasized in some cases. There is suggestive evidence that injection of testosterone into some strains of female mice increases their susceptibility to hepatoma. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats. Mutagenesis Testosterone was negative in the in vitro Ames and in the in vivo mouse micronucleus assays. Impairment of Fertility The administration of exogenous testosterone suppressed spermatogenesis and impaired fertility in the rat, dog, and non-human primate, which was reversible on cessation of treatment. A reproductive toxicology study was conducted in rats to evaluate functional effects of KYZATREX™ on male fertility. In untreated female rats mated with males receiving 2 times the maximum recommended human daily dose (MRHDD) of KYZATREX™ (based on mean AUC exposure to testosterone), the number of impregnated females was reduced, fertility was significantly lower, and pre-implantation loss was significantly higher compared to the control group. There was no impairment of fertility in males receiving an equivalent dose of KYZATREX™ to the MRHDD.

13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis Testosterone has been tested by subcutaneous injection and implantation in mice and rats. In mice, the implant induced cervical-uterine tumors, which metastasized in some cases. There is suggestive evidence that injection of testosterone into some strains of female mice increases their susceptibility to hepatoma. Testosterone is also known to increase the number of tumors and decrease the degree of differentiation of chemically induced carcinomas of the liver in rats. Mutagenesis Testosterone was negative in the in vitro Ames and in the in vivo mouse micronucleus assays. Impairment of Fertility The administration of exogenous testosterone suppressed spermatogenesis and impaired fertility in the rat, dog, and non-human primate, which was reversible on cessation of treatment. A reproductive toxicology study was conducted in rats to evaluate functional effects of KYZATREX™ on male fertility. In untreated female rats mated with males receiving 2 times the maximum recommended human daily dose (MRHDD) of KYZATREX™ (based on mean AUC exposure to testosterone), the number of impregnated females was reduced, fertility was significantly lower, and pre-implantation loss was significantly higher compared to the control group. There was no impairment of fertility in males receiving an equivalent dose of KYZATREX™ to the MRHDD. 13.2 Animal Toxicology and/or Pharmacology A 3-month repeat-dose oral toxicity study in male eugonadal dogs was conducted to evaluate whether phytosterol esters present in the KYZATREX™ formulation influenced target organ toxicity due to their structural similarities to sex steroids like testosterone. KYZATREX™ doses 2 times the MRHDD (based on mean AUC exposure to testosterone) produced similar effects on androgen-responsive tissues as testosterone undecanoate without phytosterol esters. These included mild to marked effects on the testes (decreased size, germ cell depletion, Leydig cell atrophy), epididymides (aspermia), adrenal glands (vacuolation in the zona fasciculata) and prostate (increased size and glandular hypertrophy/hyperplasia). Following a 4-week treatment-free period, findings in the testes, epididymides, and adrenal glands were not fully reversible at doses of 2 times the MRHDD of KYZATREX™ as compared to treatment with the excipients alone, including phytosterol esters. Reversibility was not assessed in testosterone undecanoate groups without phytosterol esters.

NDA213953

Kyzatrex

TESTOSTERONE UNDECANOATE

80603-103

HUMAN PRESCRIPTION DRUG

ORAL

image description image description image description Label 60

Manufactured for: Marius Pharmaceuticals LLC Raleigh, NC 27615 Issued 07/2022 200026767 Rev. 07/22

17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Medication Guide). Increase in Blood Pressure and Cardiovascular Risk Inform patients that KYZATREX™ can increase blood pressure (BP) which can result in an increase in the risk of major adverse cardiovascular events (MACE), including myocardial infarction, stroke, and cardiovascular death. This risk is greater in patients with established cardiovascular disease or risk factors for cardiovascular disease [see Warnings and Precautions (5.1) ]. Instruct patients about the importance of monitoring BP periodically while on KYZATREX™. Instruct patients to report to their healthcare provider the use of concomitant prescription or nonprescription medication, including cough and cold medication which can also increase BP [see Warnings and Precautions (5.3) ]. Polycythemia Advise patients that KYZATREX™ can cause an increase in hemoglobin/hematocrit levels that may increase the risk of thromboembolic events. Advise patients about the importance of completing laboratory testing as instructed by their health care provider while on KYZATREX™ [see Warnings and Precautions (5.2) ]. Worsening of Benign Prostatic Hyperplasia (BPH) and Potential Risk of Prostate Cancer Advise patients that KYZATREX™ can cause increased symptoms of BPH and can increase the risk for prostate cancer. Advise patients to contact their health care provider if they have any prostate-related symptoms [see Warnings and Precautions (5.4) ]. Edema Advise patients that KYZATREX™ can cause edema in patients with preexisting cardiac, renal, or hepatic disease. Advise patients to notify their health care provider if edema develops or worsens [see Warnings and Precautions (5.10) ]. Sleep Apnea Advise patients that KYZATREX™ can worsen sleep apnea especially in patients with risk factors such as obesity or chronic lung diseases ™ [see Warnings and Precautions (5.11) ]. Gynecomastia Advise patients that KYZATREX™ can cause gynecomastia [see Warnings and Precautions (5.12) ]. Administration Instructions Advise patients to take KYZATREX™ with food [see Dosage and Administration (2.3) ].

33ZATREX ™ (testosterone undecanoate) capsules, for oral use CIII This Medication Guide has been approved by the U.S. Food and Drug Administration Issued: 09/2022 MEDICATION GUIDE KYZATREX ™ (ky-ZAH-treks) (testosterone undecanoate) capsules, for oral use, CIII What is the most important information I should know about KYZATREX™? KYZATREX™ can cause serious side effects, including: Increase in blood pressure . KYZATREX™ can increase your blood pressure, which can increase your risk of having a heart attack or stroke and can increase your risk of death due to a heart attack or stroke. Your risk may be greater if you have already had a heart attack or stroke or if you have other risk factors for heart attack or stroke. If your blood pressure increases while on KYZATREX™, blood pressure medicines may need to be started. If you are taking blood pressure medicines, new blood pressure medicines may need to be added or your current blood pressure medicines may need to be changed to control your blood pressure. If your blood pressure cannot be controlled, KYZATREX™ may need to be stopped. Your healthcare provider will monitor your blood pressure while you are being treated with KYZATREX™. What is KYZATREX ™ ? KYZATREX™ is a prescription medicine that contains testosterone. KYZATREX™ is used to treat adult men who have low or no testosterone due to certain medical conditions. It is not known if KYZATREX™ is safe or effective in children younger than 18 years old. Improper use of KYZATREX™ may affect bone growth in children. KYZATREX™ is a controlled substance (CIII) because it contains testosterone that can be a target for people who abuse prescription medicines. Keep your KYZATREX™ in a safe place to protect it. Never give your KYZATREX™ to anyone else, even if they have the same symptoms you have. Selling or giving away this medicine may harm others and is against the law. KYZATREX™ is not meant for use by women. Do not take KYZATREX ™ if you: have breast cancer. have or might have prostate cancer. are a woman who is pregnant. KYZATREX™ may harm your unborn baby. are allergic to KYZATREX™ or any ingredients in KYZATREX™. See the end of this Medication Guide for a complete list of ingredients in KYZATREX™. have low testosterone without certain medical conditions. For example, do not take KYZATREX™ if you have low testosterone due to age. Before you take KYZATREX™ , tell your healthcare provider about all of your medical conditions, including if you: have high blood pressure or are treated for high blood pressure. have a history of diabetes. have heart problems. have high red blood cell count (hematocrit) or high hemoglobin laboratory value. have urinary problems due to an enlarged prostate. have liver or kidney problems. have problems breathing while you sleep (sleep apnea). Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking KYZATREX™ with certain other medicines can affect each other. Especially, tell your healthcare provider if you take : insulin medicines that decrease blood clotting (blood thinners) corticosteroids medicines that increase blood pressure such as some cold medicine and pain medicines Know the medicines you take. Ask your healthcare provider or pharmacist for a list of these medicines, if you are not sure. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. How should I take KYZATREX ™ ? Take KYZATREX™ exactly as your healthcare provider tells you take it. Take KYZATREX™ by mouth 2 times daily. Take 1 time in the morning and take 1 time in the evening. If your dose is 100 mg daily, take 1 time in the morning. Take KYZATREX™ with food. Your healthcare provider may change your KYZATREX™ dose. Do not change your KYZATREX™ dose without talking to your healthcare provider. What are the possible side effects of KYZATREX ™ ? KYZATREX ™ may cause serious side effects including: See " What is the most important information I should know about KYZATREX ™ ?" Increase in red blood cell count (hematocrit) or hemoglobin. KYZATREX™ increases red blood cell counts in some patients. High red blood cell counts increase the risk of blood clots, strokes, and heart attacks. You may need to stop KYZATREX™ if your red blood cell count increases. Your healthcare provider should check your red blood cell count and hemoglobin while you take KYZATREX™. If you already have an enlarged prostate, your signs and symptoms may worsen while taking KYZATREX ™ . These may include: increased urination at night trouble starting your urine stream urinating many times during the day urge to go to the bathroom right away a urine accident inability to pass urine or weak urine flow Increased risk of prostate cancer . Your healthcare provider should check you for prostate cancer or any other prostate problems before you start and while you take KYZATREX™. Blood clots in the legs or lungs . Signs and symptoms of a blood clot in your leg can include pain, swelling or redness. Signs and symptoms of a blood clot in your lungs can include difficulty breathing or chest pain. Abuse . Testosterone can be abused, when taken at higher than prescribed doses and when used with other anabolic androgenic steroids. Abuse can cause serious heart and psychological side effects. Your healthcare provider should check you for signs of abuse before and during treatment with KYZATREX™. In large doses KYZATREX ™ may lower your sperm count. Liver problems. Symptoms of liver problems may include: nausea or vomiting yellowing of your skin or whites of your eyes dark urine pain on the right side of your stomach area (abdominal pain) Swelling of your ankles, feet, or body (edema), with or without heart failure. Enlarged or painful breasts. Breathing problems while you sleep (sleep apnea). Call your healthcare provider right away if you have any of the serious side effects listed above. The most common side effect of KYZATREX ™ is high blood pressure. Other side effects may include headache, joint or back pain, diarrhea, increased red blood cell count, anxiety, constipation, swelling of the legs, and increased prostate specific antigen (PSA) levels. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of KYZATREX™. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store KYZATREX ™ ? Store KYZATREX™ at room temperature between 68°F to 77°F (20°C to 25°C). Store KYZATREX™ in a dry place. Keep KYZATREX ™ and all medicines out of the reach of children. How should I throw away (dispose of) KYZATREX ™ ? Throw away unused KYZATREX™ via a take-back option. If a take-back option is unavailable, follow FDA instructions at www.fda.gov/drugdisposal for properly throwing away medicine. General information about the safe and effective use of KYZATREX ™ Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use KYZATREX™ for a condition for which it was not prescribed. Do not give KYZATREX™ to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about KYZATREX™ that is written for health professionals. What are the ingredients in KYZATREX ™ ? Active ingredient: testosterone undecanoate Inactive ingredients: DL-alpha-tocopheryl acetate (Vitamin E), phytosterol esters, polyoxyl 40 hydrogenated castor oil and propylene glycol monolaurate. The ingredients of the gelatin capsule shells are gelatin, glycerin, purified water, sorbitol, and titanium dioxide. Manufactured for: Marius Pharmaceuticals Raleigh, NC 27615 For more information, go to www.KYZATREX.com or call 1-833-949-5040 200026767 Rev. 09/22

14 CLINICAL STUDIES The efficacy and safety of KYZATREX™ were evaluated in Study MRS-TU-2019EXT (NCT04467697) a multi-center, open-label study of approximately 6 months of duration in 155 hypogonadal males. Patients received KYZATREX™ at a starting dose of 200 mg twice daily with meals. The dosage was adjusted on Days 28 and 56 between a minimum dose of 100 mg (single morning dose) and a maximum dose of 800 mg (400 mg twice daily) based on plasma testosterone concentration from a single blood draw between 3 to 5 hours after the morning dose. The primary efficacy endpoint was the percentage of KYZATREX™-treated patients with mean plasma total testosterone concentration (C avg ) over 24-hours within the normal range of 222-800 ng/dL on the final PK visit of the study at Day 90. The efficacy population consisted of 139 hypogonadal, males with a median age of 50 years (range 22 to 66 years), 79% were White, 16% were Black, 3% were Asian, and 2% were American Indian, Alaskan Native or Other. Primary efficacy results are summarized in Table 6. Table 6: Proportion of Patients in Study MRS-TU-2019EXT with Average Plasma Total Testosterone in the Normal Range (222-800 ng/dL) on Day 90 Parameter N=139 C avg = 24-hour average concentration Patients (%) with Testosterone, C avg (ng/dL), 222-800 ng/dL 122 (88%) 95% Confidence Interval (82%, 93%) Secondary endpoints were the percentage of patients with a maximum total testosterone concentration (C max ) meeting three predetermined limits: less than or equal to 1.5 times the upper limit of normal range (ULN) (1200 ng/dL), between 1.8 and 2.5 times ULN (1440-2000 ng/dL), and greater than 2.5 times ULN (2000 ng/dL). The percentage of patients who received KYZATREX™ and had testosterone Cmax threshold less than or equal to 1200 ng/dL, between 1440 and 2000 ng/dL, and greater than 2000 ng/dL at the final PK visit were 88%, 4%, and 0%, respectively.

8.5 Geriatric Use Clinical studies of KYZATREX™ did not include any patients 65 years of age and older. Therefore, it cannot be determined whether these patients respond differently from younger adult patients. Additionally, there are insufficient long-term safety data in geriatric patients to assess the potentially increased risk of cardiovascular disease and prostate cancer. Geriatric patients treated with androgens including KYZATREX™ may be at risk for worsening of signs and symptoms of BPH [see Warnings and Precautions (5.4) ] .

8.4 Pediatric Use The safety and efficacy of KYZATREX™ in pediatric patients less than 18 years old have not been established. KYZATREX™ is not recommended for use in patients less than 18 years of age because of the potential for acceleration of bone age and premature closure of epiphyses.

8.1 Pregnancy Risk Summary KYZATREX™ is contraindicated in pregnant women and not indicated for use in females [see Contraindications (4) ]. Testosterone is teratogenic and may cause fetal harm when administered to a pregnant woman based on data from animal studies (see Data ) and its mechanism of action [see Clinical Pharmacology (12.1) ]. Exposure of a female fetus to androgens may result in varying degrees of virilization. In animal developmental studies, exposure to testosterone in utero resulted in hormonal and behavioral changes in offspring and structural impairments of reproductive tissues in female and male offspring. These studies do not meet current standards for nonclinical development toxicity studies. Data Animal Data In developmental studies conducted in rats, rabbits, pigs, sheep, and rhesus monkeys, pregnant animals received intramuscular injections of testosterone during the period of organogenesis. Testosterone treatment at doses that were comparable to those used for testosterone replacement therapy resulted in structural impairments in both female and male offspring. Structural impairments observed in females included increased anogenital distance, phallus development, empty scrotum, no external vagina, intrauterine growth retardation, reduced ovarian reserve, and increased ovarian follicular recruitment. Structural impairments seen in male offspring included increased testicular weight, larger seminal tubular lumen diameter, and higher frequency of occluded tubule lumen. Increased pituitary weight was seen in both sexes. Testosterone exposure in utero also resulted in hormonal and behavioral changes in offspring. Hypertension was observed in pregnant female rats and their offspring exposed to doses approximately twice those used for testosterone replacement therapy.

8 USE IN SPECIFIC POPULATIONS Geriatric Patients: Geriatric patients treated with androgens may also be at risk for worsening of signs and symptoms of BPH and hypertension ( 8.5 ). 8.1 Pregnancy Risk Summary KYZATREX™ is contraindicated in pregnant women and not indicated for use in females [see Contraindications (4) ]. Testosterone is teratogenic and may cause fetal harm when administered to a pregnant woman based on data from animal studies (see Data ) and its mechanism of action [see Clinical Pharmacology (12.1) ]. Exposure of a female fetus to androgens may result in varying degrees of virilization. In animal developmental studies, exposure to testosterone in utero resulted in hormonal and behavioral changes in offspring and structural impairments of reproductive tissues in female and male offspring. These studies do not meet current standards for nonclinical development toxicity studies. Data Animal Data In developmental studies conducted in rats, rabbits, pigs, sheep, and rhesus monkeys, pregnant animals received intramuscular injections of testosterone during the period of organogenesis. Testosterone treatment at doses that were comparable to those used for testosterone replacement therapy resulted in structural impairments in both female and male offspring. Structural impairments observed in females included increased anogenital distance, phallus development, empty scrotum, no external vagina, intrauterine growth retardation, reduced ovarian reserve, and increased ovarian follicular recruitment. Structural impairments seen in male offspring included increased testicular weight, larger seminal tubular lumen diameter, and higher frequency of occluded tubule lumen. Increased pituitary weight was seen in both sexes. Testosterone exposure in utero also resulted in hormonal and behavioral changes in offspring. Hypertension was observed in pregnant female rats and their offspring exposed to doses approximately twice those used for testosterone replacement therapy. 8.2 Lactation Risk Summary KYZATREX™ is not indicated for use in females. 8.3 Females and Males of Reproductive Potential Infertility Males During treatment with large doses of exogenous androgens, including KYZATREX™, spermatogenesis may be suppressed through feedback inhibition of the hypothalamicpituitary-testicular axis [see Warnings and Precautions (5.8) and Impairment of Fertility (13.1) ] , possibly leading to adverse effects on semen parameters including sperm count. Reduced fertility has been observed in some men taking testosterone replacement therapy. Testicular atrophy, subfertility, and infertility have also been reported in men who abuse anabolic androgenic steroids [see Drug Abuse and Dependence (9.2) ]. With either type of use, the impact on fertility may be irreversible. 8.4 Pediatric Use The safety and efficacy of KYZATREX™ in pediatric patients less than 18 years old have not been established. KYZATREX™ is not recommended for use in patients less than 18 years of age because of the potential for acceleration of bone age and premature closure of epiphyses. 8.5 Geriatric Use Clinical studies of KYZATREX™ did not include any patients 65 years of age and older. Therefore, it cannot be determined whether these patients respond differently from younger adult patients. Additionally, there are insufficient long-term safety data in geriatric patients to assess the potentially increased risk of cardiovascular disease and prostate cancer. Geriatric patients treated with androgens including KYZATREX™ may be at risk for worsening of signs and symptoms of BPH [see Warnings and Precautions (5.4) ] .

16 HOW SUPPLIED/STORAGE AND HANDLING KYZATREX™ capsules are available in three strengths of 100 mg, 150 mg, and 200 mg. It is packaged in wide-mouth, round, white HDPE bottles with white, polypropylene, child resistant caps and induction-sealed liner. 100 mg: Oval, opaque, white capsules imprinted with "MP100" in red ink supplied in bottles; NDC 80603-101-11 for 90 capsules and NDC 80603-101-22 for 120 capsules. 150 mg: Oblong, opaque, white capsules imprinted with "MP150" in red ink supplied in bottles; NDC 80603-103-11 for 90 capsules and NDC 80603-103-22 for 120 capsules. 200 mg: Oblong, opaque, white capsules imprinted with "MP200" in red ink supplied in bottles; NDC 80603-105-33 for 60 capsules , NDC 80603-105-11 for 90 capsules and NDC 80603-105-22 for 120 capsules . Store at 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store the capsules in a dry place avoiding exposure to excessive moisture and humid conditions. Dispose of unused KYZATREX™ via a take-back option. If a take-back option is unavailable, follow FDA instructions at www.fda.gov/drugdisposal.

Store at 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Store the capsules in a dry place avoiding exposure to excessive moisture and humid conditions. Dispose of unused KYZATREX™ via a take-back option. If a take-back option is unavailable, follow FDA instructions at www.fda.gov/drugdisposal.

WARNING: BLOOD PRESSURE INCREASES KYZATREX™ can cause blood pressure (BP) increases that can increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke and cardiovascular death, with greater risk for MACE in patients with cardiovascular risk factors or established cardiovascular disease [see Warnings and Precautions (5.1 , 5.3) and Adverse Reactions (6.1) ]. Before initiating KYZATREX™, consider the patient's baseline cardiovascular risk and ensure blood pressure is adequately controlled [see Warnings and Precautions (5.3) ]. After initiating therapy, periodically monitor for and treat new-onset hypertension or exacerbations of pre-existing hypertension [see Warnings and Precautions (5.1) ] . Re-evaluate whether the benefits of KYZATREX™ outweigh its risks in patients who develop cardiovascular risk factors or cardiovascular disease while on treatment [see Warnings and Precautions (5.3) ] . Due to this risk, use KYZATREX™ only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies [see Indications and Usage (1) and Contraindications (4) ]. WARNING: BLOOD PRESSURE INCREASES See full prescribing information for complete boxed warning KYZATREX™ can cause blood pressure (BP) increases that can increase the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke and cardiovascular death ( 5.1 , 5.3 , 6.1 ). Before initiating KYZATREX™, consider the patient's baseline cardiovascular risk and ensure blood pressure is adequately controlled ( 5.1 , 5.3 ). Periodically monitor for and treat new-onset hypertension or exacerbations of pre-existing hypertension and re-evaluate whether the benefits of KYZATREX™ outweigh its risks in patients who develop cardiovascular risk factors or cardiovascular disease on treatment ( 5.1 , 5.3 ). Due to this risk, use KYZATREX™ only for the treatment of men with hypogonadal conditions associated with structural or genetic etiologies ( 1 , 4 ).